share_log

Cassava Sciences | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.2%)

Cassava Sciences | SC 13G/A:超過5%持股股東披露文件(修正)-BlackRock, Inc.(7.2%)

SEC announcement ·  01/26 16:29
Moomoo AI 已提取核心訊息
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on January 26, 2024, indicating a 7.2% ownership stake in Cassava Sciences, a biopharmaceutical company. The filing, which reflects the state of ownership as of December 31, 2023, shows that BlackRock possesses sole voting power over 2,987,094 shares and sole dispositive power over 3,037,415 shares of Cassava Sciences' common stock. This amendment is a routine disclosure required by financial regulations for entities that have significant ownership in public companies. The filing also includes a list of entities under BlackRock that beneficially own 5% or greater of the outstanding shares of Cassava Sciences, as well as a power of attorney document detailing the authorization of certain individuals to act on behalf of BlackRock in fulfilling reporting requirements.
BlackRock, Inc., a major investment management corporation based in Delaware, has filed an amended Schedule 13G with the Securities and Exchange Commission on January 26, 2024, indicating a 7.2% ownership stake in Cassava Sciences, a biopharmaceutical company. The filing, which reflects the state of ownership as of December 31, 2023, shows that BlackRock possesses sole voting power over 2,987,094 shares and sole dispositive power over 3,037,415 shares of Cassava Sciences' common stock. This amendment is a routine disclosure required by financial regulations for entities that have significant ownership in public companies. The filing also includes a list of entities under BlackRock that beneficially own 5% or greater of the outstanding shares of Cassava Sciences, as well as a power of attorney document detailing the authorization of certain individuals to act on behalf of BlackRock in fulfilling reporting requirements.
總部位於特拉華州的大型投資管理公司貝萊德公司已於2024年1月26日向美國證券交易委員會提交了經修訂的附表13G,表示擁有生物製藥公司木薯科學7.2%的所有權。該文件反映了截至2023年12月31日的所有權狀況,顯示貝萊德擁有對2,987,094股股票的唯一投票權和對3,037,415股普通股的唯一處置權。該修正案是財務監管要求對上市公司擁有重要所有權的實體進行的例行披露。該文件還包括貝萊德旗下實益擁有木薯科學5%或以上已發行股份的實體清單,以及一份授權書文件,其中詳細說明了某些個人代表貝萊德行事以履行報告要求的授權。
總部位於特拉華州的大型投資管理公司貝萊德公司已於2024年1月26日向美國證券交易委員會提交了經修訂的附表13G,表示擁有生物製藥公司木薯科學7.2%的所有權。該文件反映了截至2023年12月31日的所有權狀況,顯示貝萊德擁有對2,987,094股股票的唯一投票權和對3,037,415股普通股的唯一處置權。該修正案是財務監管要求對上市公司擁有重要所有權的實體進行的例行披露。該文件還包括貝萊德旗下實益擁有木薯科學5%或以上已發行股份的實體清單,以及一份授權書文件,其中詳細說明了某些個人代表貝萊德行事以履行報告要求的授權。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息